← Back to Browse
Ask AleraHome
NUCLEAR
Whole Body SkeletonDemonstration data

Tc-99m MDP Bone Scintigraphy

Bone scintigraphy uses Tc-99m-labelled diphosphonates (MDP or HDP) that adsorb onto hydroxyapatite in proportion to osteoblastic activity and regional blood flow. It is a highly sensitive whole-body survey for skeletal disease, detecting osteoblastic turnover before radiographic change. The optional three-phase technique (dynamic flow, blood-pool and delayed images) distinguishes soft-tissue from osseous pathology and is particularly useful for infection and complex regional pain syndrome.

Indications

  • Detection and monitoring of osteoblastic skeletal metastases (breast, prostate, lung)
  • Suspected osteomyelitis and diabetic foot infection using the three-phase technique
  • Occult, stress or insufficiency fractures not evident on radiographs
  • Evaluation of painful joint prostheses for loosening versus infection
  • Assessment of metabolic bone disease, Paget disease, and complex regional pain syndrome

Contraindications & Cautions

  • Pregnancy is a relative contraindication; defer unless the benefit outweighs fetal dose
  • Breastfeeding: interruption is generally not required with Tc-99m diphosphonates, but close/prolonged infant contact and feeding immediately post-injection are minimised per local rules
  • No absolute contraindications otherwise; ensure the patient can lie still for imaging
  • Recent nuclear medicine studies with residual tracer may degrade image quality — check prior administrations
  • Renal impairment prolongs soft-tissue background but is not a contraindication; optimise hydration

Patient Preparation

  • No fasting required; encourage oral hydration after injection to improve target-to-background ratio
  • Void immediately before delayed imaging to reduce bladder activity and pelvic obscuration
  • Remove metallic objects and coins from pockets that could cause attenuation artefacts
  • Delay of 2-4 hours between injection and delayed static/whole-body images for bone uptake and soft-tissue clearance
  • Confirm pregnancy status and recent radiopharmaceutical or radiographic contrast administration

Technique & Parameters

  • Inject Tc-99m MDP/HDP 740-1110 MBq (20-30 mCi) intravenously
  • Three-phase option: (1) dynamic flow (radionuclide angiogram) over ~60 s, (2) immediate blood-pool image, (3) delayed images at 2-4 h
  • Acquire whole-body anterior and posterior planar sweeps with a large field-of-view gamma camera and high-resolution collimator
  • Add SPECT or SPECT/CT for problem-solving (spine, pelvis, feet) to localise and characterise lesions
  • Optional fourth-phase (24 h) delayed images improve specificity in osteomyelitis with poor renal clearance

Systematic Review

  • Assess tracer distribution symmetry, kidney and bladder visualisation, and overall image quality
  • On three-phase studies, correlate flow and blood-pool with delayed uptake to localise pathology
  • Review the whole skeleton systematically: skull, axial spine, ribs, pelvis, and appendicular bones
  • Identify focal versus diffuse uptake and any photopenic (cold) defects
  • Correlate suspicious foci with SPECT/CT or radiographs to distinguish benign degenerative from metastatic disease

Key Findings & Significance

  • Multiple randomly distributed focal foci in the axial skeleton and ribs favour metastatic disease
  • Superscan: diffusely increased skeletal uptake with faint or absent renal and soft-tissue activity ("absent kidney sign") from widespread metastases or metabolic bone disease
  • Three-phase positivity in all phases at bone suggests osteomyelitis; blood-pool-only positivity suggests cellulitis/soft-tissue infection
  • Photopenic (cold) lesions occur with aggressive lytic metastases (e.g. renal, myeloma), infarction or avascular disease
  • Flare phenomenon: apparent increase in uptake at 3-6 months after successful therapy reflecting healing, not progression

Differential Considerations

  • Solitary focus: fracture, degenerative change, metastasis, osteoid osteoma, Paget disease
  • Multiple foci: metastases, healing/traumatic fractures (linear, aligned with ribs), polyostotic Paget or fibrous dysplasia
  • Superscan: diffuse osteoblastic metastases, renal osteodystrophy, hyperparathyroidism, osteomalacia
  • Photopenic lesion: aggressive lytic metastasis, myeloma, bone infarct, radiotherapy port, avascular necrosis (early)
  • Periarticular uptake: osteoarthritis, inflammatory arthropathy, complex regional pain syndrome (periarticular pattern)

Pearls & Pitfalls

  • Rib metastases are typically rounded and randomly placed, whereas traumatic fractures align linearly along a rib and at consecutive levels
  • The flare phenomenon can mimic progression — interpret early post-treatment scans with the clinical and biochemical picture
  • SPECT/CT dramatically improves specificity in the spine and feet by localising uptake to a benign or malignant substrate
  • A superscan can be missed because it looks "too good" — the absent-kidney sign is the clue
  • Purely lytic lesions (myeloma, renal cell) may be normal or cold on bone scan; correlate with skeletal survey or FDG PET

Structured Report

  • State tracer, injected activity, phases performed and any SPECT/CT
  • Describe the pattern and distribution of abnormal uptake and any photopenic defects
  • Correlate with prior imaging and note flare versus true progression on treatment follow-up
  • Give a probability of metastatic disease and recommend correlative imaging where indicated
  • Provide a concise impression addressing the referring clinical question

References

  • Van den Wyngaert T, et al. The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging 2016
  • SNMMI Procedure Standard for Bone Scintigraphy 3.0
  • Love C, et al. Radionuclide bone imaging: an illustrative review. RadioGraphics 2003
  • Palestro CJ, et al. Combined labeled leukocyte and technetium-99m sulfur colloid bone marrow imaging for diagnosing musculoskeletal infection. RadioGraphics 2006

Educational clinical decision support only. Protocols vary by institution and equipment; always confirm with a qualified radiologist and local guidelines before clinical use.